Dashboard
Manage Tickers

LUMO LUMOS PHARMA, INC.


$ 0.00 (0 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 611.58 $ -1.93 (-0.32 %)
DIA $ 470.32 $ 0.58 (0.12 %)
SPY $ 672.03 $ 0.66 (0.1 %)
TLT $ 89.47 $ -0.19 (-0.21 %)
GLD $ 367.88 $ 2.24 (0.61 %)
$ 4.34
-- x --
-- x --
-- - --
$ 1.37 - $ 4.58
481,687
na
37.54M
$ -3.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lumos-pharma-presents-updated-phase-2-oragrowth-data-demonstrating-sustained-growth-on-oral-lum-201-to-24-months-in-pghd-and-correlation-of-growth-to-lum-201s-unique-pulsatile-mechanism-of-action-at-espe-2024
Lumos Pharma Presents Updated Phase 2 OraG...
11/21/2024 14:15:05

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announc...

hc-wainwright--co-reiterates-neutral-on-lumos-pharma-maintains-425-price-target
HC Wainwright & Co. Reiterates Neutral on ...
11/08/2024 16:22:30

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Neutral and maintains $4.25 price ...

analyst-expectations-for-lumos-pharmas-future
Analyst Expectations For Lumos Pharma's Fu...
10/24/2024 19:00:24

hc-wainwright--co-downgrades-lumos-pharma-to-neutral-lowers-price-target-to-425
HC Wainwright & Co. Downgrades Lumos Pharm...
10/24/2024 18:53:43

HC Wainwright & Co. analyst Edward White downgrades Lumos Pharma (NASDAQ:LUMO) from Buy to Neutral and lowers the price ...

jones-trading-downgrades-lumos-pharma-to-hold-lowers-price-target-to-425
Jones Trading Downgrades Lumos Pharma to H...
10/23/2024 21:09:57

Jones Trading analyst Lina Kaminski downgrades Lumos Pharma (NASDAQ:LUMO) from Buy to Hold and lowers the price target from ...

trading-halt-halt-status-updated-at-82500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:25:...
10/23/2024 12:25:05

lumos-pharma-enters-into-go-private-agreement-with-double-point-ventures-for-tender-offer-of-425-cash-per-share
Lumos Pharma Enters Into Go Private Agreem...
10/23/2024 12:03:55

lumos-pharma-shares-halted-news-pending
Lumos Pharma Shares Halted, News Pending
10/23/2024 11:56:49

trading-halt-halted-at-75500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:55:00 a.m. ET - ...
10/23/2024 11:55:04

hc-wainwright--co-reiterates-buy-on-lumos-pharma-maintains-28-price-target
HC Wainwright & Co. Reiterates Buy on Lumo...
09/27/2024 15:00:52

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.

lumos-pharma-announces-abstract-accepted-for-oral-presentation-at-the-13th-biennial-scientific-meeting-of-the-asia-pacific-pediatric-endocrine-society-appes-2024
Lumos Pharma Announces Abstract Accepted F...
09/25/2024 20:08:52

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announc...

ef-hutton-initiates-coverage-on-lumos-pharma-with-buy-rating-announces-price-target-of-16
EF Hutton Initiates Coverage On Lumos Phar...
09/24/2024 12:51:10

EF Hutton analyst Jason Kolbert initiates coverage on Lumos Pharma (NASDAQ:LUMO) with a Buy rating and announces Price Targe...

oppenheimer-maintains-outperform-on-lumos-pharma-lowers-price-target-to-13
Oppenheimer Maintains Outperform on Lumos ...
08/02/2024 15:50:21

Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and lowers the price target from ...

lumos-pharma-q2-2024-gaap-eps-093-beats-124-estimate-sales-488000k-beat-333333k-estimate
Lumos Pharma Q2 2024 GAAP EPS $(0.93) Beat...
08/01/2024 20:40:00

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.24) ...

lumos-pharma-reports-new-analyses-of-phase-2-oragrowth212-trial-at-endo-2024
Lumos Pharma Reports New Analyses Of Phase...
06/04/2024 13:01:01

lumos-pharma-q1-2024-gaap-eps-129-misses-118-estimate-sales-16500k-miss-30260k-estimate
Lumos Pharma Q1 2024 GAAP EPS $(1.29) Miss...
05/14/2024 20:53:18

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18...

lumos-pharma-announces-positive-end-of-phase-2-meeting-with-fda-co-expects-to-finalize-design-details-with-fda-in-q3-and-be-in-position-to-initiate-trial-before-end-of-year
Lumos Pharma Announces Positive End-of-Pha...
05/14/2024 20:16:57

lumos-pharma-announces-abstracts-reviewing-data-from-its-phase-2-oragrowth210-and-oragrowth212-trials-will-be-presented-at-upcoming-medical-meetings
Lumos Pharma Announces Abstracts Reviewing...
04/18/2024 20:08:11

hc-wainwright--co-reiterates-buy-on-lumos-pharma-maintains-28-price-target
HC Wainwright & Co. Reiterates Buy on Lumo...
03/20/2024 16:29:58

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.

lumos-pharma-announces-uspto-has-granted-patent-protection-for-novel-formulation-of-lum-201-extending-exclusivity-to-2042
Lumos Pharma Announces USPTO Has Granted P...
03/20/2024 12:06:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION